On the stock market since 1998, it operates in the world of health and science. It has 389 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 7% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades 29% below its peak. The market has trimmed its expectations for the company.
Sales run at $126.1M a year. A small number, but proof the product has real buyers.
There is $40.1M in the vault; even if every debt were paid off, $6.9M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
A loss of $11.5M against $126.1M in annual sales. And on top of that, sales fell from the year before.
Over the last 12 months, executives reported 107 sells against just 8 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, SRDX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SRDX is a high-risk stock — not yet profitable, and its future rides on its product catching on.